Team Leader in Drug Discovery Biology for Paediatric Brain Tumours

03/09/2018, 23:55

Sutton
Full time
Fixed Term
35
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally.

The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.

In February 2018, Cancer Research UK (CRUK) launched the CRUK Children’s Brain Tumour Centre of Excellence (CRUK-CBTCE) to create a hub of expertise and drive progress in paediatric brain cancers. Led by Professor Richard Gilbertson at the University of Cambridge and Professor Paul Workman at the ICR, the centre will unite teams across the research pipeline at the two locations. It will have a particular focus on drug discovery for paediatric tumours, drawing on the strengths of the CRUK Cancer Therapeutics Unit at the ICR.

This is a unique opportunity to establish one of the first academic drug discovery groups focused on paediatric brain cancers as part of an exciting collaboration. This research group will focus on target identification and drug discovery in order to transform the way in which treatments are discovered for children with brain tumours.  They will focus on identifying and validating novel therapeutic targets in paediatric brain cancers and lead the biology of drug discovery projects against well validated targets including projects that aim to repurpose existing drugs. 

We consider all applications on merit and have a strong commitment to enhancing the diversity of our staff.

In partnership with

Cancer Research UK
Additional Documentation for Candidates

This Program is closed to applications.